{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:10:12Z","timestamp":1788952212385,"version":"build-2803163510"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background &amp;amp; aims<\/jats:title>\n                    <jats:p>People with HIV (PWH) who achieve hepatitis C virus (HCV) cure may retain persistent metabolic alterations, particularly those with advanced fibrosis or cirrhosis. This study aimed to characterize plasma metabolomic and lipidomic profiles associated with cirrhosis in PWH at one and five years post-HCV therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two cross-sectional studies evaluated PWH one (n=48) and five (n=30) years post-HCV therapy. Cirrhosis was defined as a liver stiffness measurement (LSM)\u226512.5 kPa. Metabolomics and lipidomics were performed using capillary electrophoresis-mass spectrometry (CE-MS) and liquid chromatography-mass spectrometry (LC-MS), respectively. Data were analyzed using orthogonal partial least squares discriminant analysis (OPLS-DA) and generalized linear models (GLM), adjusting for relevant covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At one and five years, 32 (66.7%) and 10 (33.3%) participants, respectively, had cirrhosis. OPLS-DA identified 235 and 229 metabolites with variable importance in projection (VIP) scores &amp;gt;1. At one year, cirrhosis was associated with elevated levels of glycerophospholipids, sphingomyelins, and amino acids, and lower levels of triglycerides. At five years, cirrhotic PWH exhibited higher levels of glycerophospholipids and acyl-carnitines, together with lower levels of triglycerides and amino acids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PWH with cirrhosis post-HCV cure exhibits a persistently altered metabolic profile stable for five years, suggesting ongoing systemic inflammation and liver disease progression. These findings underscore the need for continued long-term monitoring of this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1932664","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:36Z","timestamp":1788948996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic alterations associated with cirrhosis after HCV cure in people with HIV: metabolomic and lipidomic findings at one and five years"],"prefix":"10.3389","volume":"17","author":[{"given":"Ana","family":"Virseda-Berdices","sequence":"first","affiliation":[{"name":"Unidad de Infecci\u00f3n Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III","place":["Majadahonda, Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]},{"name":"Facultad de Medicina, Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Fern\u00e1ndez-Requena","sequence":"additional","affiliation":[{"name":"Centro de Metabol\u00f3mica y Bioan\u00e1lisis, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanizaci\u00f3n Montepr\u00edncipe","place":["Boadilla del Monte, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]},{"name":"Unidad de Enfermedades Infecciosas\/VIH, Hospital General Universitario Gregorio Mara\u00f1\u00f3n","place":["Madrid, Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"G\u00f3nzalez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]},{"name":"Servicio de Medicina Interna\u2013Unidad de VIH, Hospital Universitario La Paz","place":["Madrid, Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Paz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gonzalez-Riano","sequence":"additional","affiliation":[{"name":"Centro de Metabol\u00f3mica y Bioan\u00e1lisis, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanizaci\u00f3n Montepr\u00edncipe","place":["Boadilla del Monte, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Behar-Lagares","sequence":"additional","affiliation":[{"name":"Unidad de Infecci\u00f3n Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III","place":["Majadahonda, Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"D\u00edez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]},{"name":"Unidad de Enfermedades Infecciosas\/VIH, Hospital General Universitario Gregorio Mara\u00f1\u00f3n","place":["Madrid, Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Honta\u00f1\u00f3n","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]},{"name":"Servicio de Medicina Interna\u2013Unidad de VIH, Hospital Universitario La Paz","place":["Madrid, Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Paz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Unidad de Infecci\u00f3n Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III","place":["Majadahonda, Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Barbas","sequence":"additional","affiliation":[{"name":"Centro de Metabol\u00f3mica y Bioan\u00e1lisis, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanizaci\u00f3n Montepr\u00edncipe","place":["Boadilla del Monte, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Martin-Escolano","sequence":"additional","affiliation":[{"name":"Unidad de Infecci\u00f3n Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III","place":["Majadahonda, Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Resino","sequence":"additional","affiliation":[{"name":"Unidad de Infecci\u00f3n Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III","place":["Majadahonda, Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Angeles","family":"Jim\u00e9nez-Sousa","sequence":"additional","affiliation":[{"name":"Unidad de Infecci\u00f3n Viral e Inmunidad, Centro Nacional de Microbiolog\u00eda, Instituto de Salud Carlos III","place":["Majadahonda, Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0349","article-title":"Acute hepatitis C virus infection: clinical update and remaining challenges","volume":"29","author":"Liu","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.021","article-title":"Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations","volume":"71","author":"Rossi","year":"2019","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/v13112249","article-title":"A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy","volume":"13","author":"Mazzaro","year":"2021","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100036","article-title":"Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases","volume":"2","author":"Chang","year":"2024","journal-title":"eGastroenterology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002778","article-title":"Long-term risks of cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes","volume":"119","author":"Chen","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/cancers15020533","article-title":"Hepatitis virus and hepatocellular carcinoma: recent advances","volume":"15","author":"Shen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/bib\/bbw031","article-title":"Analysis of metabolomic data: tools, current strategies and future challenges for omics data integration","volume":"18","author":"Cambiaghi","year":"2017","journal-title":"Brief Bioinform"},{"key":"B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jgg.2019.11.009","article-title":"Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression","volume":"47","author":"Wang","year":"2020","journal-title":"J Genet Genomics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1578202","article-title":"Metabolic reprogramming in viral infections: the interplay of glucose metabolism and immune responses","volume":"16","author":"Darweesh","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3390\/v14061313","article-title":"Immunometabolic reprogramming in response to HIV infection is not fully normalized by suppressive antiretroviral therapy","volume":"14","author":"Deme","year":"2022","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/v16020219","article-title":"Examining chronic inflammation, immune metabolism, and T cell dysfunction in HIV infection","volume":"16","author":"Mu","year":"2024","journal-title":"Viruses"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000001787","article-title":"Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV\/hepatitis C virus-coinfected patients","volume":"32","author":"Medrano","year":"2018","journal-title":"AIDS"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcoa.2021.100018","article-title":"Exploiting the formation of adducts in mobile phases with ammonium fluoride for the enhancement of annotation in liquid chromatography-high resolution mass spectrometry based lipidomics","volume":"1","author":"Gonzalez-Riano","year":"2021","journal-title":"J Chromatogr Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2020.461758","article-title":"Enhancing confidence of metabolite annotation in Capillary Electrophoresis-Mass Spectrometry untargeted metabolomics with relative migration time and in-source fragmentation","volume":"1635","author":"Mamani-Huanca","year":"2021","journal-title":"J Chromatogr A"},{"key":"B19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1021\/acs.jproteome.8b00720","article-title":"CEU Mass Mediator 3.0: a metabolite annotation tool","volume":"18","author":"Gil-de-la-Fuente","year":"2019","journal-title":"J Proteome Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s42003-023-05680-7","article-title":"LiLA: lipid lung-based ATLAS built through a comprehensive workflow designed for an accurate lipid annotation","volume":"7","author":"Fernandez Requena","year":"2024","journal-title":"Commun Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1039\/c5an01638j","article-title":"Intra-batch effect correction in liquid chromatography-mass spectrometry using quality control samples and support vector regression (QC-SVRC)","volume":"140","author":"Kuligowski","year":"2015","journal-title":"Analyst"},{"key":"B22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/metabo11080488","article-title":"Investigating global lipidome alterations with the Lipid Network Explorer","volume":"11","author":"Kohler","year":"2021","journal-title":"Metabolites"},{"key":"B23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of cholesterol-associated steatohepatitis in the development of NASH","volume":"6","author":"Horn","year":"2022","journal-title":"Hepatol Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.07.007","article-title":"Hierarchical tricarboxylic acid cycle regulation by hepatocyte arginase 2 links the urea cycle to oxidative metabolism","volume":"36","author":"Zhang","year":"2024","journal-title":"Cell Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.3390\/nu13113764","article-title":"Amino acid profile in malnourished patients with liver cirrhosis and its modification with oral nutritional supplements: implications on minimal hepatic encephalopathy","volume":"13","author":"Espina","year":"2021","journal-title":"Nutrients"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2020.1842172","article-title":"Application of metabolomics in diagnosis and treatment of chronic liver diseases","volume":"52","author":"Tang","year":"2022","journal-title":"Crit Rev Anal Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2026.119350","article-title":"Branched-chain amino acids and innate immunity in metabolic disease: mechanisms, paradox, and therapeutic opportunities","volume":"198","author":"Martinez-Aguilar","year":"2026","journal-title":"BioMed Pharmacother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106604","article-title":"Emerging role for branched-chain amino acids metabolism in fibrosis","volume":"187","author":"Wu","year":"2023","journal-title":"Pharmacol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13856","article-title":"Branched-chain amino acid metabolism: pathophysiological mechanism and therapeutic intervention in metabolic diseases","volume":"26","author":"Mansoori","year":"2025","journal-title":"Obes Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i43.7620","article-title":"Branched-chain amino acids in liver diseases","volume":"19","author":"Tajiri","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/nu16121875","article-title":"Branched-chain amino acids in liver diseases: complexity and controversy","volume":"16","author":"Zhang","year":"2024","journal-title":"Nutrients"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nutres.2019.11.009","article-title":"Zinc and protein metabolism in chronic liver diseases","volume":"74","author":"Katayama","year":"2020","journal-title":"Nutr Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12876-025-03655-y","article-title":"Machine learning-based plasma metabolomics for improved cirrhosis risk stratification","volume":"25","author":"Song","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2023.101238","article-title":"Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): recent advances","volume":"91","author":"Musso","year":"2023","journal-title":"Prog Lipid Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26738","article-title":"Phospholipid profiles and hepatocellular carcinoma risk and prognosis in cirrhotic patients","volume":"10","author":"Cotte","year":"2019","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v12.i8.436","article-title":"Lipidomics in non-alcoholic fatty liver disease","volume":"12","author":"Kartsoli","year":"2020","journal-title":"World J Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.05.015","article-title":"Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients","volume":"56","author":"Babu","year":"2024","journal-title":"Dig Liver Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.043","article-title":"Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis","volume":"75","author":"Claria","year":"2021","journal-title":"J Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130346","article-title":"Circulating lipids are associated with alcoholic liver cirrhosis and represent potential biomarkers for risk assessment","volume":"10","author":"Meikle","year":"2015","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094645","article-title":"The role of phospholipid alterations in mitochondrial and brain dysfunction after cardiac arrest","volume":"25","author":"Choudhary","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.002","article-title":"Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction","author":"Engelmann","year":"2021","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms161226225","article-title":"Oxidative stress and inflammation in hepatic diseases: therapeutic possibilities of N-acetylcysteine","volume":"16","author":"de Andrade","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3892\/etm.2021.10034","article-title":"Interrelation of inflammation and oxidative stress in liver cirrhosis","volume":"21","author":"Pomacu","year":"2021","journal-title":"Exp Ther Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c170012","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr Physiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12944-022-01716-9","article-title":"Role of triglycerides as a predictor of autoimmune hepatitis with cirrhosis","volume":"21","author":"Wang","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12944-018-0898-y","article-title":"Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis","volume":"17","author":"Liu","year":"2018","journal-title":"Lipids Health Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00003.2020","article-title":"The role of the sphingolipid pathway in liver fibrosis: an emerging new potential target for novel therapies","volume":"318","author":"Ishay","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/cancers16050850","article-title":"Critical roles of the sphingolipid metabolic pathway in liver regeneration, hepatocellular carcinoma progression and therapy","volume":"16","author":"Nojima","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9806","DOI":"10.3390\/ijms23179806","article-title":"Serum ceramide species are associated with liver cirrhosis and viral genotype in patients with hepatitis C infection","volume":"23","author":"Horing","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-012-5782-4","article-title":"Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases","volume":"403","author":"Zhou","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.121.000408","article-title":"Acylcarnitines: Nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials","volume":"74","author":"Dambrova","year":"2022","journal-title":"Pharmacol Rev"},{"key":"B52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12876-020-01190-6","article-title":"Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients","volume":"20","author":"Miyaaki","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101187","article-title":"Palmitoylcarnitine impairs immunity in decompensated cirrhosis","volume":"6","author":"Zhang","year":"2024","journal-title":"JHEP Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/biom11020281","article-title":"Serum acylcarnitines associated with high short-term mortality in patients with alcoholic hepatitis","volume":"11","author":"Gao","year":"2021","journal-title":"Biomolecules"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:37Z","timestamp":1788948997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2026.1932664"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1932664","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1932664"}}